Date lodged: 19 September 2018
To ask the Scottish Government whether the drug, Rezum, for the treatment for benign prostatic hyperplasia (BPH) is available in Scotland, and, if not, for what reasons it is not included in SIGN guidelines.
Answered by: Joe FitzPatrick 5 October 2018
The Scottish Government is aware that Rezum has recently been recommended by NICE and could be considered as an additional treatment for NHS Scotland patients. However, the role of the Scottish Government is to provide policies, frameworks and resources to NHS Boards to allow them to deliver services that meet the needs of their local populations. Within this context, the actual provision of healthcare services, is the responsibility of local Boards, taking into account national guidance, local service needs and priorities for investment.